A Phase I, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Inhaled AZD8630 in Adolescents With Asthma
Latest Information Update: 20 Oct 2025
At a glance
- Drugs AZD 8630 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Acronyms APkITA
- Sponsors AstraZeneca
Most Recent Events
- 14 Oct 2025 Status changed from recruiting to completed.
- 20 Aug 2025 Planned number of patients changed from 19 to 18.
- 20 Aug 2025 Planned End Date changed from 25 Feb 2026 to 13 Feb 2026.